SynapDx this week appointed Andrew Conrad to the company's board of directors.
Conrad recently joined Google to participate in its Google X investigative laboratory. He previously served as chief scientific officer and executive vice president of Laboratory Corporation of America and is co-founder of its National Genetics Institute.
Conrad's appointment coincided with Google Ventures' recent investment in SynapDx, which is developing expression array-based tests for autism (see related story, this issue).
CombiMatrix has appointed Robert Hoffman to its board of directors.
Hoffman has been senior vice president of finance and chief financial officer at Arena Pharmaceuticals, a San Diego-based biopharma company, since 1997. He is also a member of the business and financial advisory board of Innovus Pharmaceuticals, a La Jolla, Calif.-based pharmaceuticals company.